Of the 667 adult participants who are obese or overweight, those who received 50 milligrams of semaglutide “achieved a superior weight loss of 15.1 percent compared to a reduction of 2.4 percent with placebo, and 84.9 percent achieved a weight loss of 5 percent or more, compared to 25.8 percent with placebo,” drugmaker Novo Nordisk said May 22 in a news release.
If all people adhered to the treatment for 68 weeks, the average weight loss would be 17.4 percent, compared to the placebo’s 1.8 percent reduction.
Novo Nordisk said it plans to file for regulatory approval in 2023.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
